Akebia Therapeutics, Inc. (NasdaqCM: AKBA)
Health Care · Biotechnology · US
$0.90
-0.66% today · -70.1% 1Y
Akebia Therapeutics, Inc. (NasdaqCM: AKBA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $251.22M and employs 194 people.
Over the last twelve months the share price has lost 70.1%, trading between 0.81 and 3.32.
Tweenvest scores Akebia Therapeutics, Inc. across four factors: quality 44/100, value 66/100, growth 0/100. Its strongest factor is value.
AKBA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $251.22M
- Revenue (TTM)
- $219.06M
- P/E
- —
- EPS
- -0.11
- Dividend yield
- —
- Beta (5Y)
- 0.24
- 52-week high
- $3.32
- 52-week low
- $0.81
- Avg volume (3M)
- —
- Shares outstanding
- 277.11M
- Employees
- 194
- Next earnings
- —
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
- ISIN
- US00972D1054
- Founded
- 2007
- Listed since
- Mar 20, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.